Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy

Volume: 16, Issue: 12, Pages: 725 - 726
Published: Oct 3, 2019
Abstract
BRCA1/2 mutations and poly (ADP-ribose) polymerase (PARP) inhibitors are paradigmatic of synthetic lethal therapy. However, the activity of PARP inhibitors seems to vary considerably across BRCA1/2-mutant cancers and new insights into the tumour-lineage dependency of this synthetic lethal relationship might explain why BRCA1/2 mutations are not tumour-agnostic biomarkers of a response to PARP...
Paper Details
Title
Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy
Published Date
Oct 3, 2019
Volume
16
Issue
12
Pages
725 - 726
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.